Latest Breaking News On - Roby zomer - Page 70 : comparemela.com

MGC Pharmaceuticals (ASX:MXC) to list on London Stock Exchange

In an effort to broaden its international profile, MGC Pharmaceuticals (ASX:MXC) says it's in the final stages of listing its shares on the London Stock Exchange.

City ofUnited kingdomTurner popeRoby zomerLondon stock exchangeLondon stockMiddle eastManaging directorநகரம் ஆஃப்ஒன்றுபட்டது கிஂக்டம்டர்னர் போப்ராபி ஜோமேற்லண்டன் ஸ்டாக் பரிமாற்றம்லண்டன் ஸ்டாக்நடுத்தர கிழக்குநிர்வகித்தல் இயக்குனர்

Cannabis company lists in London to fund Covid trial

Cannabis company lists in London to fund Covid trial Australia s MGC Pharmaceuticals aims to raise £5m to fund final-stage trials of anti-inflammatory Covid treatment called Artemic 1 February 2021 • 3:54pm An Australian medicinal cannabis company is preparing to list in London to help fund clinical trials for a marijuana-derived Covid treatment. MGC Pharmaceuticals will be just the second medical cannabis outfit to list on the London Stock Exchange, after the financial regulator changed the rules last year, paving the way for companies like MGC to raise funds with a listing. It hopes to raise £5m to help cover the costs of final-stage clinical trials for an experimental anti-inflammatory Covid treatment called Artemic.

United kingdomCity ofOxford nanoporeRoby zomerBoris johnsonAuction technology groupLondon stock exchangeNextenergy renewablesDr martensTa associatesMiddle eastTechnology groupAqua commsTriple point investmentEnergy renewablesஒன்றுபட்டது கிஂக்டம்

Cannabis, auctions, digital assets and renewables companies line up for London IPOs

Cannabis, auctions, digital assets and renewables companies line up for London IPOs
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofRoby zomerAmerica bidspotterHelium one group ltdAuction technology groupEcofin us renewablesPineapple power corpWildcat petroleumImpact trustAqua ventures ltdNextenergy renewables limitedTechnology groupNorth america bidspotterAuction mobilityJohn paul savant

Proactive Investors China - The web s leading portal for China stocks - MGC Pharma higher as ArtemiC Phase II clinical trial on COVID-19 patients meets all primary and secondary endpoints

2020-12-15 by Proactive Australia MGC Pharmaceuticals Ltd s (ASX:MXC)(OTCMKTS:MGCLF)(FRA:H5O) Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment ArtemiC, based on Swiss PharmaCan AG MyCell Enhanced TM delivery system technology, on those diagnosed with COVID-19, has met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of the patients. The European-based biopharma company specialising in the production and development of phytocannabinoid-derived medicines is now in a strong position to respond to a significant potential increase in the demand for ArtemiC in the immediate future as a supplement, and in the future as part of a Phase III study.

Roby zomerPharmaceuticals ltdArtemic phaseSwiss pharmacanInvestigational medicinal productராபி ஜோமேற்மருந்துகள் லிமிடெட்